Drug Design
portes grátis
Drug Design
From Structure and Mode-of-Action to Rational Design Concepts
Klebe, Gerhard
Springer-Verlag Berlin and Heidelberg GmbH & Co. KG
02/2025
686
Dura
9783662689974
15 a 20 dias
Descrição não disponível.
Preface.- Introduction.- Part I Fundamentals of drug research.- 1 Drug research yesterday, today, tomorrow.- 2 In the beginning there was serendipity.- 3 Examples of classical drug research.- 4 Protein-ligand interactions as the basis of drug action.- 5 Optical activity and biological action.- Part II The search for lead structure.- 6 The classical search for lead structure.- 7 Screening technologies for lead structure search.- 8 The optimisation of lead structure.- 9 The design of prodrugs.- 10 Peptidomimetics. 6 The classical search for lead structure.- 7 Screening technologies for lead structure search.- 8 Lead structure optimisation.- 9 Design of prodrugs.- 10 Peptidomimetics.Part III Experimental and theoretical methods.- 11 Combinatorics: chemistry with large numbers.- 12 Genetic engineering in drug discovery.- 13 Experimental methods for structure elucidation.- 14 Description of the structure of biomolecules.- 15 Molecular modelling.- 16 Conformational analysis.- Part IV Quantitative structure-activity relationships and design methods.- 17 Pharmacophore hypotheses, molecular comparisons and database searches.- 18 Quantitative structure-activity relationships.- 19 From in vitro to in vivo: optimising ADME tox properties.- 20 Protein modelling and structure-based drug design.- 21 An example: structure-based design of inhibitors of tRNA-guanine transglycosylase.- Part V Successes in rational drug design.- 22 How drugs work: targets for therapy.- 23 Inhibitors for hydrolases with acyl enzyme intermediates.- 24 Inhibitors of aspartyl proteases.- 25 Inhibitors of hydrolytically cleaving metalloenzymes.- 26 Inhibitors for transferases.- 27 Inhibitors for oxidoreductases.- 28 Agonists and antagonists for nuclear receptors.- 29 Agonists and antagonists of membrane receptors.- 30 Ligands for channels, pores and transporters.- 31 Ligands for surface receptors.- 32 Biopharmaceuticals: peptides, proteins, nucleotides and macrolides as active substances.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Drug Design;Biomolecules;Nucleotides;Pharmacy;Proteins;Transport;Mode-of-action;Substances
Preface.- Introduction.- Part I Fundamentals of drug research.- 1 Drug research yesterday, today, tomorrow.- 2 In the beginning there was serendipity.- 3 Examples of classical drug research.- 4 Protein-ligand interactions as the basis of drug action.- 5 Optical activity and biological action.- Part II The search for lead structure.- 6 The classical search for lead structure.- 7 Screening technologies for lead structure search.- 8 The optimisation of lead structure.- 9 The design of prodrugs.- 10 Peptidomimetics. 6 The classical search for lead structure.- 7 Screening technologies for lead structure search.- 8 Lead structure optimisation.- 9 Design of prodrugs.- 10 Peptidomimetics.Part III Experimental and theoretical methods.- 11 Combinatorics: chemistry with large numbers.- 12 Genetic engineering in drug discovery.- 13 Experimental methods for structure elucidation.- 14 Description of the structure of biomolecules.- 15 Molecular modelling.- 16 Conformational analysis.- Part IV Quantitative structure-activity relationships and design methods.- 17 Pharmacophore hypotheses, molecular comparisons and database searches.- 18 Quantitative structure-activity relationships.- 19 From in vitro to in vivo: optimising ADME tox properties.- 20 Protein modelling and structure-based drug design.- 21 An example: structure-based design of inhibitors of tRNA-guanine transglycosylase.- Part V Successes in rational drug design.- 22 How drugs work: targets for therapy.- 23 Inhibitors for hydrolases with acyl enzyme intermediates.- 24 Inhibitors of aspartyl proteases.- 25 Inhibitors of hydrolytically cleaving metalloenzymes.- 26 Inhibitors for transferases.- 27 Inhibitors for oxidoreductases.- 28 Agonists and antagonists for nuclear receptors.- 29 Agonists and antagonists of membrane receptors.- 30 Ligands for channels, pores and transporters.- 31 Ligands for surface receptors.- 32 Biopharmaceuticals: peptides, proteins, nucleotides and macrolides as active substances.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
